Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None2021202020192018201720162015 Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer 07/20/2018 Poseida Therapeutics Appoints John P. Schmid to Board of Directors 07/19/2018 Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA 04/26/2018 Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma 04/17/2018 Poseida Raises $30.5 Million in Series B Financing 04/03/2018 Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018 03/26/2018 Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer 02/28/2018 Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies 02/14/2018 Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations 02/05/2018 Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple Myeloma 12/18/2017 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Next page next › Last page last » Displaying 31 - 40 of 61
Year None2021202020192018201720162015 Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer 07/20/2018 Poseida Therapeutics Appoints John P. Schmid to Board of Directors 07/19/2018 Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA 04/26/2018 Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma 04/17/2018 Poseida Raises $30.5 Million in Series B Financing 04/03/2018 Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018 03/26/2018 Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer 02/28/2018 Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies 02/14/2018 Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations 02/05/2018 Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple Myeloma 12/18/2017 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Next page next › Last page last » Displaying 31 - 40 of 61
Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer 07/20/2018
Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA 04/26/2018
Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma 04/17/2018
Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018 03/26/2018
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer 02/28/2018
Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies 02/14/2018
Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations 02/05/2018
Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple Myeloma 12/18/2017